Skip to main content
. 2020 Apr 6;12(4):701–711. doi: 10.4168/aair.2020.12.4.701

Fig. 3. Serum levels of OM-specific Ig measured via enzyme-linked immunosorbent assay on days 1 (on OIT) and 14 after discontinuation of OIT and/or Lcr35 treatment. (A) OM-specific IgE levels, (B) OM-specific IgA levels, (C) OM-specific IgG1 levels, and (D) OM-specific IgG2a levels.

Fig. 3

OM, ovomucoid; OIT, oral immunotherapy; Ig, immunoglobulin.

*P < 0.05 compared to the control group (vs. No OIT); †P < 0.05 compared to the OIT group (vs. OIT).